annual cash & cash equivalents:
$3.65B-$826.54M(-18.45%)Summary
- As of today (September 9, 2025), NVO annual cash & cash equivalents is $3.65 billion, with the most recent change of -$826.54 million (-18.45%) on December 31, 2024.
- During the last 3 years, NVO annual cash & cash equivalents has risen by +$979.63 million (+36.64%).
- NVO annual cash & cash equivalents is now -18.45% below its all-time high of $4.48 billion, reached on December 31, 2023.
Performance
NVO Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$2.98B-$3.04B(-50.48%)Summary
- As of today (September 9, 2025), NVO quarterly cash & cash equivalents is $2.98 billion, with the most recent change of -$3.04 billion (-50.48%) on June 1, 2025.
- Over the past year, NVO quarterly cash & cash equivalents has dropped by -$6.03 billion (-66.92%).
- NVO quarterly cash & cash equivalents is now -73.43% below its all-time high of $11.21 billion, reached on September 30, 2024.
Performance
NVO quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
NVO Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -18.4% | -66.9% |
| 3 y3 years | +36.6% | -31.7% |
| 5 y5 years | +57.1% | -20.5% |
NVO Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -18.4% | +36.6% | -73.4% | +121.2% |
| 5 y | 5-year | -18.4% | +74.2% | -73.4% | +145.9% |
| alltime | all time | -18.4% | +8547.1% | -73.4% | +2288.9% |
NVO Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $2.98B(-50.5%) |
| Mar 2025 | - | $6.02B(+64.7%) |
| Dec 2024 | $3.65B(-18.5%) | $3.65B(-67.4%) |
| Sep 2024 | - | $11.21B(+24.5%) |
| Jun 2024 | - | $9.00B(+568.5%) |
| Mar 2024 | - | $1.35B(-69.9%) |
| Dec 2023 | $4.48B(+32.4%) | $4.48B(-33.7%) |
| Sep 2023 | - | $6.76B(+26.7%) |
| Jun 2023 | - | $5.33B(+31.7%) |
| Mar 2023 | - | $4.05B(+19.7%) |
| Dec 2022 | $3.38B(+26.6%) | $3.38B(-31.5%) |
| Sep 2022 | - | $4.94B(+13.2%) |
| Jun 2022 | - | $4.36B(+44.8%) |
| Mar 2022 | - | $3.01B(+12.7%) |
| Dec 2021 | $2.67B(+27.5%) | $2.67B(-51.5%) |
| Sep 2021 | - | $5.52B(+27.1%) |
| Jun 2021 | - | $4.34B(+258.3%) |
| Mar 2021 | - | $1.21B(-42.2%) |
| Dec 2020 | $2.10B(-9.8%) | $2.10B(-47.8%) |
| Sep 2020 | - | $4.01B(+7.1%) |
| Jun 2020 | - | $3.75B(+161.1%) |
| Mar 2020 | - | $1.44B(-38.2%) |
| Dec 2019 | $2.32B(-3.0%) | $2.32B(-15.1%) |
| Sep 2019 | - | $2.74B(+24.2%) |
| Jun 2019 | - | $2.21B(+62.0%) |
| Mar 2019 | - | $1.36B(-43.1%) |
| Dec 2018 | $2.40B(-29.8%) | $2.40B(-7.6%) |
| Sep 2018 | - | $2.59B(-13.1%) |
| Jun 2018 | - | $2.98B(+41.9%) |
| Mar 2018 | - | $2.10B(-38.4%) |
| Dec 2017 | $3.41B(+13.3%) | $3.41B(-1.1%) |
| Sep 2017 | - | $3.45B(-2.6%) |
| Jun 2017 | - | $3.54B(+36.3%) |
| Mar 2017 | - | $2.60B(-13.7%) |
| Dec 2016 | $3.01B(-0.4%) | $3.01B(+16.4%) |
| Sep 2016 | - | $2.59B(+9.5%) |
| Jun 2016 | - | $2.36B(+50.4%) |
| Mar 2016 | - | $1.57B(-48.1%) |
| Dec 2015 | $3.02B(+16.8%) | $3.02B(+11.7%) |
| Sep 2015 | - | $2.71B(+48.4%) |
| Jun 2015 | - | $1.82B(+70.6%) |
| Mar 2015 | - | $1.07B(-58.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2014 | $2.59B(-12.3%) | $2.59B(+12.0%) |
| Sep 2014 | - | $2.31B(+86.9%) |
| Jun 2014 | - | $1.24B(+9.7%) |
| Mar 2014 | - | $1.13B(-61.8%) |
| Dec 2013 | $2.95B(-1.9%) | $2.95B(+11.0%) |
| Sep 2013 | - | $2.66B(-11.6%) |
| Dec 2012 | $3.01B(-1.8%) | $3.01B(-1.2%) |
| Sep 2012 | - | $3.05B(+43.7%) |
| Jun 2012 | - | $2.12B(-11.6%) |
| Mar 2012 | - | $2.40B(-25.2%) |
| Dec 2011 | $3.07B(+6.1%) | - |
| Jun 2011 | - | $3.21B(+10.9%) |
| Dec 2010 | $2.89B(+1076.8%) | $2.89B(+21.4%) |
| Sep 2010 | - | $2.38B(+20.8%) |
| Jun 2010 | - | $1.97B(+6.5%) |
| Mar 2010 | - | $1.85B(+60.5%) |
| Sep 2007 | - | $1.15B(+14.3%) |
| Jun 2007 | - | $1.01B(+16.9%) |
| Mar 2007 | - | $862.51M(+123.6%) |
| Mar 2004 | - | $385.75M(+57.1%) |
| Dec 2002 | $245.54M(-59.6%) | $245.54M(+25.3%) |
| Dec 2001 | - | $196.03M(+23.3%) |
| Dec 2000 | - | $159.01M(-7.3%) |
| Dec 1999 | $608.00M(+42.4%) | $171.62M(+37.6%) |
| Dec 1998 | $426.90M(-27.7%) | $124.70M(-24.3%) |
| Dec 1997 | $590.30M(+24.4%) | $164.71M(+7.1%) |
| Dec 1996 | $474.66M(-29.4%) | $153.76M(-71.5%) |
| Dec 1995 | $672.50M(+0.7%) | $540.42M(-50.8%) |
| Dec 1994 | $667.98M(+27.3%) | $1.10B(+30.4%) |
| Dec 1993 | $524.63M(-15.8%) | $842.90M(-9.4%) |
| Dec 1992 | $623.29M(-15.7%) | $930.22M(-8.9%) |
| Dec 1991 | $739.57M(+43.6%) | $1.02B(+36.0%) |
| Dec 1990 | $514.85M(+15.1%) | $750.32M(+68.4%) |
| Dec 1989 | $447.28M(+22.3%) | $445.58M(+21.6%) |
| Dec 1988 | $365.59M(+9.5%) | $366.29M(+9.2%) |
| Dec 1987 | $334.00M(+23.1%) | $335.56M(+23.7%) |
| Dec 1986 | $271.22M(+15.5%) | $271.32M(+15.6%) |
| Dec 1985 | $234.86M(+23.8%) | $234.75M(+23.7%) |
| Dec 1984 | $189.65M(+6.1%) | $189.82M |
| Dec 1983 | $178.78M(+107.3%) | - |
| Dec 1982 | $86.25M(-20.2%) | - |
| Dec 1981 | $108.06M(+155.8%) | - |
| Dec 1980 | $42.25M | - |
FAQ
- What is Novo Nordisk A/S annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Novo Nordisk A/S?
- What is Novo Nordisk A/S annual cash & cash equivalents year-on-year change?
- What is Novo Nordisk A/S quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Novo Nordisk A/S?
- What is Novo Nordisk A/S quarterly cash & cash equivalents year-on-year change?
What is Novo Nordisk A/S annual cash & cash equivalents?
The current annual cash & cash equivalents of NVO is $3.65B
What is the all time high annual cash & cash equivalents for Novo Nordisk A/S?
Novo Nordisk A/S all-time high annual cash & cash equivalents is $4.48B
What is Novo Nordisk A/S annual cash & cash equivalents year-on-year change?
Over the past year, NVO annual cash & cash equivalents has changed by -$826.54M (-18.45%)
What is Novo Nordisk A/S quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of NVO is $2.98B
What is the all time high quarterly cash & cash equivalents for Novo Nordisk A/S?
Novo Nordisk A/S all-time high quarterly cash & cash equivalents is $11.21B
What is Novo Nordisk A/S quarterly cash & cash equivalents year-on-year change?
Over the past year, NVO quarterly cash & cash equivalents has changed by -$6.03B (-66.92%)